TORONTO, Jan. 19 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD), a medical systems company focused on evolving laboratory-based biomarker testing, today announced that Professor Yehuda Shoenfeld, MD., has joined SQI's Scientific Advisory Board as Chairman to support the development of the Company's IgXPLEX(TM) assay and platform development pipeline.
Shoenfeld is currently Head, Department of Medicine 'B' and Center for Autoimmune Diseases, Sheba Medical Center, and Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel. He has authored many scientific papers and more than 40 scientific books and serves as editor of several medical journals.
"We look forward to working with Dr. Shoenfeld as we continue to develop SQI's multiplex microarray clinical assay diagnostic platforms," said Claude Ricks, SQI's CEO. "Dr. Shoenfeld's experience will be invaluable to our Scientific Advisory Board and we look forward to his insight and guidance."
In November, 2009, the U.S. Food and Drug Administration cleared SQI's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States. The technology provides clinical laboratories with access to a cost-effective and highly efficient diagnosis platform to simultaneously analyze multiple biomarkers and deliver accurate patient results.
SQI's IgXPLEX(TM) product pipeline for 2010 includes the highest-demand autoimmune test panels for Celiac Disease, Vasculitis, Lupus and Irritable Bowel Disease (Crohn's disease, ulcerative colitis).
About SQI Diagnostics
SQI Diagnostics is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. SQI provides laboratories the ability to simultaneously analyze multiple biomarkers, deliver accurate patient results in less time, significantly reduce labour, and increase profits...All in One Drop. For more information please visit www.sqidiagnostics.com.
Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.
For further information: For further information: Chief Financial Officer, Andrew Morris, (416) 674-9500 ext. 229, email@example.com; Media and Investor Relations, Adam Peeler, (416) 815-0700 ext. 225, firstname.lastname@example.org